Blinatumomab Bridge Therapy for Mitigating Chemotoxicity in Children with Acute Lymphoblastic Leukemia
We report two pediatric patients with pre-B ALL, treated with blinatumomab because of chemotherapy-associated toxicity, with recovery and successful bridging to further chemotherapy. Blinatumomab can be considered in pediatric ALL patients who develop chemotherapy toxicity and whose treatment is delayed.
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Blood Transusion | Cancer | Cancer & Oncology | Chemotherapy | Children | Hematology | India Health | Leukemia | Pediatrics | Toxicology